BCL2 and acute myeloid leukemia: BH3-mimetic agents that directly trigger apoptosis in cancer cells reliant on BCL-2 or its pro-survival relatives have emerged as powerful agents for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [1].